EcoDrugPlus

Mitogen-Activated Protein Kinase Kinase 2b

Ensembl ID : ENSAPEG00000012403
Gene Symbol: MAP2K2B
1 Cross references
202 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase Kinase 10

Ensembl ID : ENSAPEG00000024356
Gene Symbol: MAP3K10
1 Cross references
183 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase Kinase 12

Ensembl ID : ENSAPEG00000008165
Gene Symbol: MAP3K12
2 Cross references
184 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase Kinase 12

Ensembl ID : ENSAPEG00000017464
Gene Symbol: MAP3K12
1 Cross references
191 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase Kinase 13

Ensembl ID : ENSAPEG00000015656
Gene Symbol: MAP3K13
1 Cross references
201 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase Kinase 5

Ensembl ID : ENSAPEG00000006044
Gene Symbol: MAP3K5
1 Cross references
205 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase Kinase 8

Ensembl ID : ENSAPEG00000003120
Gene Symbol: MAP3K8
1 Cross references
201 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase Kinase 9

Ensembl ID : ENSAPEG00000008905
Gene Symbol: MAP3K9
1 Cross references
194 Possible Orthologues:

Monoglyceride Lipase

Ensembl ID : ENSAPEG00000012213
Gene Symbol: MGLL
1 Cross references
208 Possible Orthologues:

Motilin Receptor

Ensembl ID : ENSAPEG00000011910
Gene Symbol: MLNR
1 Cross references
172 Possible Orthologues:

Natriuretic Peptide Receptor 1a

Ensembl ID : ENSAPEG00000018483
Gene Symbol: NPR1A
1 Cross references
194 Possible Orthologues:

Natriuretic Peptide Receptor 2

Ensembl ID : ENSAPEG00000020904
Gene Symbol: NPR2
2 Cross references
191 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).